Sideromycin 7
Sideromycin 7 is an antibacterial agent. Sideromycin 7 forms a 7-Bi3+ coordination complex with bismuth citrate, exerting a three-pronged antibacterial mode of action: direct DNA binding to induce damage and arrest replication, suppression of KdpC synthesis to block KdpFABC-mediated potas-sium transport, and inhibition of ATP production. Sideromycin 7 exhibits potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains. Sideromycin 7 exerts antibiofilm activity against Pseudomonas aeruginosa. Sideromycin 7 can be used for the research of ciprofloxacin-resistant Pseudomonas aeruginosa infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C28H36FN5O7
- Masse moléculaire:573.61
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Sideromycin 7 acts synergistically with bismuth citrate to exhibit potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains, with MICs 3.2- to 21-fold lower than conventional quinolone antibiotics[1].
Sideromycin 7 (combined with bismuth citrate; 18 days daily passaging) does not induce resistance development in Pseudomonas aeruginosa 859 or 7034 after 18 days of serial passaging in vitro[1].
Sideromycin 7 (combined with bismuth citrate; 4× MIC; 24 h) significantly inhibits Pseudomonas aeruginosa 541 biofilm formation by 78% after 24 h of incubation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sideromycin 7 (2-32 mg/kg; intraperitoneal injection; two doses total) reduces bacterial burden and lung inflammation in a neutropenic mouse lung infection model[1].
Sideromycin 7 (32 mg/kg; intraperitoneal injection; once daily; 28 days) is well-tolerated in mice with no observable toxicity or gut microbiota disruption[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 4-6 weeks old, 18-20 g, subcutaneous implantation of PDMS sheets precoated with P. aeruginosa 7034 biofilms)[1]
-
Dosage:8 mg/kg
-
Administration:in situ injection; once daily; 3 days
-
Result:Reduced log10 CFU/mL of bacterial burden on PDMS sheets compared to vehicle control.
Improved wound healing with reduced visible inflammation compared to vehicle control.
Decreased necrotic areas and inflammatory infiltrates in skin and muscle tissue relative to vehicle control.
-
Animal Model:SPF ICR (female, 6 weeks old, 20-22 g, cyclophosphamide-induced neutropenic, intranasal inoculation with P. aeruginosa 535 and 541)[1]
-
Dosage:2, 5, 8 32 mg/kg
-
Administration:intraperitoneal injection; two doses total (2 hours and 12 hours post-infection)
-
Result:Reduced log10 CFU/g of lung tissue compared to vehicle control for P.
aeruginosa 541 at 5 mg/kg, 8 mg/kg, or 32 mg/kg.
Reduced log10 CFU/g of lung tissue compared to vehicle control for P.
aeruginosa 535 at 8 mg/kg.
Reduced inflammatory cell infiltration in lung tissue relative to vehicle control.
Chemical Information
-
Masse moléculaire 573.61
-
Formule C28H36FN5O7
-
SMILES
CC(N(CCCCCNC(CCC(N1CCN(CC1)C2=C(C=C3C(C(C(O)=O)=CN(C3=C2)C4CC4)=O)F)=O)=O)O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sideromycin 7 Related Classifications
HY-181966 Related Classifications
Powered by Bioz
- Sideromycin 7
- Sideromycin7
- Sideromycin-7
- Bacterial
- DNA/RNA Synthesis
- Potassium Channel
- murine models
- oxidative phosphorylation complexes IV
- oxidative phosphorylation complexes V
- Pseudomonas aeruginosa
- KdpFABC
- gut microbiota
- potassium transport
- KdpC
- ciprofloxacin-resistant Pseudomonas aeruginosa
- DNA integrity
- Inhibitor
- inhibitor
- inhibit